In this article, we will discuss Anlotinib Tolerability (6). So, let’s get started.
Anlotinib had a similar toxicity in another phase I trial and a manageable AE profile in phase II–III trials. Among 58 patients with advanced MTC who received anlotinib treatment in a phase II study, 20.7% required a dose adjustment to 10 mg daily in a 2 weeks on/1 week off schedule because of grade III/IV AEs. It is noteworthy that 5 of 166 patients (3.01%) with advanced STS treated with anlotinib experienced grade III/IV pneumothorax. Additionally, in patients with mRCC, anlotinib induced significantly fewer cases of grade 3/4 side effects, especially thrombocytopenia and neutropenia, than sunitinib did, but caused a greater incidence of hypercholesterolemia.